Technical Note

Not just any probiotic will improve iron absorption

“Iron is hard on the gut, so pair it with a probiotic” is an intuitive pairing, and it shows up in formulations more often every year. A randomised, double-blind trial published this month in Clinical Nutrition ESPEN tested it directly in 200 adults aged 60 and over with mild-to-moderate anaemia: adding a multi-organism probiotic to daily iron and folic acid produced no additional rise in haemoglobin over 12 weeks, and ferritin rose less, not more, than with iron alone. For formulators the most useful part of this paper is not the headline but what the probiotic actually was — because that decides how far the null result travels.

Published 29 October 2026 · 8 min read

What the study did

Design

Community-based, placebo-controlled, double-blind randomised controlled trial in adults aged ≥60 years with mild-to-moderate anaemia, drawn from the AIIMS SBIMB Study on Healthy Ageing (ASTHA) cohort. 200 participants randomised 1:1.

Intervention: daily iron–folic acid tablet (60 mg elemental iron + 500 μg folic acid) plus a probiotic capsule labelled as containing Streptococcus faecalis, Bifidobacterium and Lactobacillus, 30 billion CFU per capsule.
Control: the same iron–folic acid tablet plus a placebo capsule (1 mg oral rehydration salts).
12 weeks. Outcomes: haemoglobin, ferritin, hepcidin, CRP, acute infections and gut microbiome diversity.
Intention-to-treat as the primary analysis, per-protocol as sensitivity. Registered as CTRI/2023/09/057830.

Result

184 participants completed follow-up; missing endline biochemistry was imputed by last observation carried forward.

Haemoglobin: +1.0 ± 1.1 g/dL with probiotic versus +1.2 ± 1.1 g/dL without (p = 0.439).
Hepcidin: increased in both groups, no between-group difference (p = 0.550).
Ferritin: rose more in the control group — +20.6 ± 34.2 vs +10.0 ± 20.4 ng/mL (p = 0.033).
Microbiome: alpha-diversity was higher in the intervention group at baseline; most endline diversity measures were comparable.

The authors' conclusion: iron–folic acid with probiotics did not provide additional benefit in haemoglobin or ferritin response compared with iron–folic acid alone over 12 weeks.

What it does and does not establish

What it establishes: in this population, at this dose, with this product, over this period, the probiotic did not improve the response to iron. Two hundred participants, double-blind, placebo-controlled, analysed by intention to treat — a respectable design for a nutrition intervention, with a clean result.

Two points need careful reading:

“Ferritin rose less” should not be read as “the probiotic impaired iron repletion.” Ferritin is also an acute-phase protein and rises with inflammation and infection. CRP and acute infections were measured, but their between-group results are not reported in the abstract, so the abstract alone cannot tell us whether the ferritin difference reflects iron stores or something else. With standard deviations this wide (±34.2 in the control arm), the defensible reading is “no benefit observed”, not “harm demonstrated”.

Baseline was not fully balanced. The intervention group started with higher microbial diversity and the groups converged by the end, so the trial also gives no support to the intermediate step of “the probiotic changed the microbiome”.

What it does not establish: that probiotics are useless alongside iron. The reason is the next section.

The decisive detail: no strain designations

The abstract identifies the probiotic only to genus level — Bifidobacterium, Lactobacillus — plus Streptococcus faecalis, the name Enterococcus faecalis carried before it was reclassified in 1984. None of the organisms is given a strain designation.

That bounds the result, and it cuts both ways:

It cannot be cited against any specific strain. A null result from a genus-level blend says nothing about a product with a defined, strain-level identity.

It also shows why a generic “add a probiotic” approach was never likely to work. In the probiotic–iron literature, only one strain has poolable evidence. A 2019 systematic review and meta-analysis in Nutrients (15 studies in 12 articles, N = 950) found that only Lactiplantibacillus plantarum 299v (Lp299v) had enough studies to pool, and it showed increased iron absorption in isotope studies (pooled SMD 0.55, 95% CI 0.22–0.88). For iron status, however, the evidence was weak: of seven trials across a range of probiotic species, only one — with Lp299v — reported an improvement in serum iron.

The existing evidence already has two thresholds. The first is the strain: absorption evidence follows one organism, not “lactobacilli”. The second is the endpoint: a higher fractional absorption from a labelled meal and an improvement in iron status weeks later are different questions, and the evidence for the second has always been thin. The new trial crossed neither threshold — unidentified strains, a 12-week haemoglobin endpoint. Its null result is consistent with the shape of what was already known.

One more piece of context. The trial gave 60 mg elemental iron daily, and hepcidin rose in both arms. Raised hepcidin suppresses subsequent iron absorption, which is the rationale behind recent alternate-day, lower-dose regimens — a randomised trial in European Journal of Nutrition this month reported that 21 mg every other day achieved ferritin improvements comparable to 30 mg daily in iron-deficient women. When the iron regimen itself is the limiting factor, any “enhancer” will be hard to detect. That is our inference, not a finding of this study, but it matters to whoever designs the next trial.

A note from an ingredient manufacturer

We supply lactic acid bacteria and bifidobacteria, including organisms in the same genera as this trial. So this note has to hold the line in both directions. We will not use the Lp299v evidence to suggest that any other strain of the same species improves iron absorption — evidence follows the strain, and a different strain of the same species does not inherit it. Nor will we use this null trial against anyone else's product. We are writing about it because it is an unusually clean illustration that a blend without strain identities produces results, positive or negative, that are hard to reuse.

What this means for formulators and brand owners

1. “Iron + probiotic” is not a pairing that stands on intuition

If the formulation logic is “probiotics are good for the gut, so they will help with iron”, a 200-person double-blind trial now sits on the other side of that logic. A credible pairing needs an organism with its own strain-level evidence, not a category.

2. Know whether you are citing absorption or status

Isotope absorption studies and 12-week haemoglobin trials answer different questions. Citing the former in support of anaemia-related language crosses an endpoint. Claims should stop at the endpoint that was measured.

3. Use current nomenclature on the label, and name the strain

Streptococcus faecalis has been out of use for four decades. A specification still using a superseded name, and stopping at genus, generates results that cannot be traced or reused. We have written about labelled species that did not match genome-based identification in products on sale — the first link in any evidence chain is knowing what the organism is.

4. For an enhancer formulation, get the primary regimen right first

If iron is given as a large daily dose, hepcidin regulation may already be capping absorption, leaving little room for an adjunct to show anything. In an “iron + X” trial or formulation, iron dose and dosing interval are variables, not background.

5. Older adults need their own evidence

This trial enrolled community-dwelling adults over 60. The Lp299v absorption work was carried out mainly in women of reproductive age. Evidence does not follow automatically when the population changes — in either direction.

If you are assessing this direction

Where we can help is the strain layer: confirming what an organism is at species and strain level, assembling strain-level documentation and quality-control records, and checking whether a cited study used the same strain, dose and population. We will not use any study to support an efficacy claim for a product, ours or anyone else's.

References

Impact of supplementation of a package of iron folic acid (IFA) with probiotics on haemoglobin levels in the elderly with mild to moderate anaemia: A double-blind, randomised controlled trial (PRATHAM). Clinical Nutrition ESPEN, 2026. doi:10.1016/j.clnesp.2026.105208. CTRI/2023/09/057830. PubMed record
Vonderheid SC, et al. A Systematic Review and Meta-Analysis on the Effects of Probiotic Species on Iron Absorption and Iron Status. Nutrients, 2019;11(12):2938. Full text (open access)
Hoppe M, et al. Probiotic strain Lactobacillus plantarum 299v increases iron absorption from an iron-supplemented fruit drink: a double-isotope cross-over single-blind study in women of reproductive age. British Journal of Nutrition, 2015;114:1195–1202. Full text
Reduced-dose alternate-day oral iron supplementation in women with iron deficiency: a randomized controlled trial. European Journal of Nutrition, 2026. PubMed record

This note summarises and interprets published research in order to explain how strain identity, endpoint choice and dosing regimen bound the applicability of evidence. It is not a claim about the efficacy or safety of any product, is not directed at any company or brand, and is not medical or dietary advice. Anaemia has many causes, and iron regimens should be set with a physician. Findings apply only to the populations, doses, formulations and conditions described in the original sources. Statements on microbial nomenclature are general; permitted categories are governed by the current official notices in the market concerned.